A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease.

@article{Tzimopoulou2010AMR,
  title={A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease.},
  author={Sofia Tzimopoulou and Vincent J. Cunningham and Thomas E. Nichols and Graham E. Searle and Nicholas Rowland Bird and Prafull Mistry and Ian John Dixon and William A. Hallett and Brandon Whitcher and Andrew Patrick Brown and Marina E. Zvartau-Hind and Narinder Lotay and Robert Yiu Ki Lai and Mary Castiglia and Barbara Jeter and Julian C. Matthews and Kewei Chen and Danniel Bandy and Eric M. Reiman and Michael I. Gold and Eugenii A. Rabiner and Paul M. Matthews},
  journal={Journal of Alzheimer's disease : JAD},
  year={2010},
  volume={22 4},
  pages={
          1241-56
        }
}
Here we report the first multi-center clinical trial in Alzheimer's disease (AD) using fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) measures of brain glucose metabolism as the primary outcome. We contrasted effects of 12 months treatment with the PPARγ agonist Rosiglitazone XR versus placebo in 80 mild to moderate AD patients. Secondary objectives included testing for reduction in the progression of brain atrophy and improvement in cognition. Active treatment was associated… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 26 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 53 REFERENCES

The art of drug synthesis, John W iley

  • DS Johnson, JJ Li
  • 2007
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…